Abstract |
Progressive multifocal leukoencephalopathy (PML) is the most feared complication when natalizumab ( NAT) is used in the treatment of relapsing multiple sclerosis (MS). JC virus serologic status is a currently established risk factor for PML. When seroconversion occurs, NAT discontinuation should be based on a solid rationale to avoid an MS inflammatory resurgence. The JC virus index value may also provide further useful information to help practitioners and patients in their decision process.
|
Authors | Bruno Barroso, Marie Miquel, Raluca Marasescu, Stéphanie Demasles, Elsa Krim, Mikael Bonnan |
Journal | Multiple sclerosis and related disorders
(Mult Scler Relat Disord)
Vol. 4
Issue 4
Pg. 380-2
(Jul 2015)
ISSN: 2211-0356 [Electronic] Netherlands |
PMID | 26195060
(Publication Type: Case Reports, Journal Article)
|
Copyright | Copyright © 2015 Elsevier B.V. All rights reserved. |
Chemical References |
- Antibodies, Viral
- Immunologic Factors
- Natalizumab
|
Topics |
- Adult
- Antibodies, Viral
(blood)
- Humans
- Immunologic Factors
(therapeutic use)
- JC Virus
(immunology)
- Male
- Multiple Sclerosis, Relapsing-Remitting
(drug therapy, immunology, pathology)
- Natalizumab
(therapeutic use)
- Retreatment
|